Duchenne Muscular Dystrophy (original) (raw)
Latest News for: duchenne muscular dystrophy
Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in ...
Norfolk Daily News 02 Jun 2026
Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical ... .
Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea (Nxera Pharma Co Ltd)
Public Technologies 02 Jun 2026
Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea ... About Duchenne Muscular Dystrophy ... Vamorolone is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD).
Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight ...
GetNews 29 May 2026
DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, ...
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading ...
Nasdaq Globe Newswire 26 May 2026
The Duchenne muscular dystrophy clinical trial analysis report delivers important insights ...
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) (Dyne Therapeutics Inc)
Public Technologies 26 May 2026
Food and Drug Administration (FDA) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) 20 mg/kg Q4W for the treatment of individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Montana Standard 21 May 2026
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research ... .
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy ...
Nasdaq Globe Newswire 20 May 2026
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - ... .
CureDuchenne Announces Partnership with Tevard Biosciences to Advance Suppressor tRNA Therapy for the Treatment of Duchenne Muscular Dystrophy
PR Newswire 20 May 2026
NEWPORT BEACH, Calif., May 20, 2026 /PRNewswire/ -- CureDuchenne, a global leader in funding and advancing research for Duchenne muscular dystrophy, today announced a second investment into Tevard ...
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy (Atossa Therapeutics Inc)
Public Technologies 20 May 2026
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy ... Muscular Dystrophy ... About Duchenne Muscular Dystrophy.
CureDuchenne Announces Partnership with Tevard Biosciences to Advance Suppressor tRNA Therapy for the Treatment of Duchenne Muscular Dystrophy (CureDuchenne Ventures LLC)
Public Technologies 20 May 2026
Newport Beach, Calif., May 20, 2026 -CureDuchenne, a global leader in funding and advancing research for Duchenne muscular dystrophy, today announced a second investment into Tevard Biosciences to ...
‘These kids have a chance’: John Davidson sees hope for boys with Duchenne Muscular Dystrophy
CTV 16 May 2026
Learning their son ...
UAE saves Iraqi child Youssef with world’s costliest injection for Duchenne muscular dystrophy
Gulf News 16 May 2026
“Save Youssef… A race against time before his muscles and heart fail him.”According to Al Khaleej, Youssef’s father, Haider Al Waeli, said his son received the injection after undergoing extensive ...
GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual Meeting
PR Newswire 14 May 2026
... novel, potential gene therapy for Duchenne muscular dystrophy (DMD) ... "We are excited to announce Duchenne muscular dystrophy as our latest named program," said GEMMABio Chief Executive Officer James M.
You can change the future of Duchenne muscular dystrophy - This May, The Walk to ...
Canada Newswire 13 May 2026
About Defeat Duchenne CanadaDefeat Duchenne Canada is the country's only national charity solely dedicated to ending Duchenne muscular dystrophy.
Duchenne muscular dystrophy: ‘Breakthrough’ drug for severe muscle wasting condition set for NHS rollout in England
The Independent 08 May 2026
Givinostat will be made ...